Sponsored by Gelesis Inc.

It is essential for clinicians to balance benefits and risks when choosing a weight management therapy for patients with overweight or obesity. Today, there is an urgent need for effective therapies with highly favorable safety profiles. To address this need, Gelesis has developed a nonsystemic, superabsorbent hydrogel (Plenity™) indicated to aid in weight management in overweight and obese adults with a BMI of 25-40 kg/m2, when used in conjunction with diet and exercise. This program will explore the how Plenity’s indication and favorable safety/efficacy profile may enable clinicians to intervene earlier in the overweight and obesity continuum.


Louis Aronne, MD
Sanford I. Weill Professor of Metabolic Research and Professor of Clinical Medicine
Weill Cornell Medical College, Cornell University

Ken Fujioka, MD
Director of Nutrition and Metabolic Research Center
Scripps Clinic

James Hill, PhD
Professor and Chairman, Department of Nutrition Sciences, and Director of Nutrition Obesity Research Center
University of Alabama

Harry Leider, MD
Chief Medical Officer
Gelesis Inc

Learning Objectives

  • To explore the concept of mechanobiology and understand the superabsorbent hydrogel mechanism of Plenity
  • To evaluate the safety and efficacy profile of Plenity by reviewing the available clinical trial data
  • To explore the early experience of obesity experts who have used Plenity in their practices
  • To discuss how Plenity can fit into current practice models for the treatment of overweight and obesity

Accreditation Statement: N/A

Register for this event here!